Merck & Co. Inc. closed 32.72% below its 52-week high of $134.63, which the company achieved on June 25th.

Significantly extends commercial reach of Growth Direct through expanded global sales channels; enables opportunities for ...

While Merck reported strong financial results in recent quarters, it faces both upsides and risks in the future. Read why I'm ...

Merck's Q4 2024 results surpassed expectations, driven by strong oncology sales and growth in Keytruda. See why I think MRK ...

Drugmaker Merck said on Tuesday it expects its top selling cancer therapy Keytruda to be selected in 2026 for government ...

Drugmaker Merck , known as MSD outside of the U.S. and Canada, expects to increase its workforce across its India sites by ...

Merck (NYSE:MRK) shares were on track to snap six straight sessions of gains on Wednesday, as the stock fell 2.8% at $88.87 ...

Merck shares have been under pressure amid disappointing sales trends for its Gardasil HPV vaccine. The company's broader ...

As Merck & Co. hunts for an ideal spot to set up a new commercial facility, Delaware is looking to bolster its odds with a ...

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...

Merck is bracing for the years of sales growth from oncology superstar Keytruda to take a sharp turn in 2028—and for more ...

NEW YORK, NY / ACCESS Newswire / February 27, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn ...